{
    "root": "4ce24976-cf2a-419a-82fd-1ef1efb0c031",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "EC-NAPROXEN",
    "value": "20250306",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE K90",
            "code": "RDH86HJV5Z",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14478"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)",
            "code": "74G4R6TH13",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "NAPROXEN",
            "code": "57Y76R9ATQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7476"
        }
    ],
    "indications": {
        "text": "naproxen tablets , ec-naproxen , naproxen sodium indicated : relief signs symptoms : rheumatoid arthritis osteoarthritis ankylosing spondylitis polyarticular juvenile idiopathic arthritis naproxen tablets naproxen sodium also indicated : relief signs symptoms : tendonitis bursitis acute gout management : pain primary dysmenorrhea",
        "doid_entities": [
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            },
            {
                "text": "juvenile idiopathic arthritis (DOID:676)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_676"
            },
            {
                "text": "bursitis (DOID:2965)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2965"
            },
            {
                "text": "gout (DOID:13189)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13189"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "lowest effective shortest duration consistent individual patient treatment goals . ( 2.1 ) rheumatoid arthritis , osteoarthritis , ankylosing spondylitis naproxen tablets 250 mg ( one-half tablet ) 500 mg twice daily naproxen sodium 275 mg ( one-half tablet ) 550 mg twice daily ec-naproxen 375 mg 500 mg twice daily maintain integrity enteric coating , ec-naproxen tablet broken , crushed chewed ingestion . dose may adjusted depending response patient . patients tolerate lower doses well , dose may increased naproxen 1,500 mg/day 6 months . polyarticular juvenile idiopathic arthritis naproxen tablets may allow flexible dose titration needed pediatric patients polyarticular juvenile idiopathic arthritis . liquid formulation may appropriate . recommended total daily dose naproxen approximately 10 mg/kg given 2 divided doses . dosing naproxen tablets appropriate children weighing less 50 kilograms . management pain , primary dysmenorrhea , acute tendonitis bursitis recommended starting dose 550 mg naproxen sodium naproxen sodium followed 550 mg every 12 hours 275 mg every 6 8 hours required . initial total daily dose exceed 1375 mg naproxen sodium . thereafter , total daily dose exceed 1100 mg naproxen sodium . naproxen sodium recommended management acute painful conditions prompt onset pain relief desired . acute gout recommended starting dose 750 mg naproxen tablets followed 250 mg every 8 hours attack subsided . naproxen sodium may also used starting dose 825 mg followed 275 mg every 8 hours . ec-naproxen recommended delay absorption .",
        "doid_entities": [
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            },
            {
                "text": "juvenile idiopathic arthritis (DOID:676)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_676"
            },
            {
                "text": "bursitis (DOID:2965)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2965"
            },
            {
                "text": "gout (DOID:13189)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13189"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute tendonitis bursitis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_279888"
            }
        ]
    },
    "warningsAndPrecautions": "ec-naproxen ( naproxen delayed-release tablets ) 500 mg : white , oblong coated tablets imprinted npr ec 500 one side . packaged light-resistant bottles 100. supplied : ndc 72162-1935-1 100 \u2019 ( bottle ) store 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) well-closed containers ; dispense light-resistant containers . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "naproxen tablets , ec-naproxen , naproxen sodium contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) naproxen components product [ ( 5.7 , 5.9 ) ] . history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients [ ( 5.7 , 5.8 ) ] . setting coronary artery bypass graft ( cabg ) surgery [ ( 5.1 ) ] .",
    "indications_original": "NAPROXEN Tablets, EC-NAPROXEN, and NAPROXEN SODIUM are indicated for:\n                  the relief of the signs and symptoms of:\n                  \n                     rheumatoid arthritis\n                     osteoarthritis\n                     ankylosing spondylitis\n                     polyarticular juvenile idiopathic arthritis\n                  \n                  NAPROXEN Tablets and NAPROXEN SODIUM are also indicated for:\n                  the relief of signs and symptoms of:\n                  \n                     tendonitis\n                     bursitis\n                     acute gout\n                  \n                  the management of:\n                  \n                     pain\n                     primary dysmenorrhea",
    "contraindications_original": "Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. (2.1) Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis NAPROXEN Tablets 250 mg (one-half tablet) 500 mg twice daily NAPROXEN SODIUM 275 mg (one-half tablet) 550 mg twice daily EC-NAPROXEN 375 mg or 500 mg twice daily To maintain the integrity of the enteric coating, the EC-NAPROXEN tablet should not be broken, crushed or chewed during ingestion. The dose may be adjusted up or down depending on the clinical response of the patient. In patients who tolerate lower doses well, the dose may be increased to naproxen 1,500 mg/day for up to 6 months. Polyarticular Juvenile Idiopathic Arthritis NAPROXEN Tablets may not allow for the flexible dose titration needed in pediatric patients with polyarticular juvenile idiopathic arthritis. A liquid formulation may be more appropriate. Recommended total daily dose of naproxen is approximately 10 mg/kg given in 2 divided doses. Dosing with NAPROXEN Tablets is not appropriate for children weighing less than 50 kilograms. Management of Pain, Primary Dysmenorrhea, and Acute Tendonitis and Bursitis Recommended starting dose 550 mg of naproxen sodium as NAPROXEN SODIUM followed by 550 mg every 12 hours or 275 mg every 6 to 8 hours as required. The initial total daily dose should not exceed 1375 mg of naproxen sodium. Thereafter, the total daily dose should not exceed 1100 mg of naproxen sodium. NAPROXEN SODIUM is recommended for the management of acute painful conditions when prompt onset of pain relief is desired. Acute Gout Recommended starting dose 750 mg of NAPROXEN Tablets followed by 250 mg every 8 hours until the attack has subsided. NAPROXEN SODIUM may also be used at a starting dose of 825 mg followed by 275 mg every 8 hours. EC-NAPROXEN is not recommended because of the delay in absorption.",
    "warningsAndPrecautions_original": "EC-Naproxen (naproxen delayed-release tablets)\u00a0500 mg: white, oblong coated tablets imprinted with NPR EC 500 on one side. Packaged in light-resistant bottles of 100. Supplied as:\n                  \n                  NDC 72162-1935-1 100\u2019s (bottle)\n                  Store at 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) in well-closed containers; dispense in light-resistant containers.\n                  \n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "NAPROXEN Tablets, EC-NAPROXEN, and NAPROXEN SODIUM are contraindicated in the following patients:\n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product\n  \n   [see Warnings and Precautions\n   \n    (5.7,\n   \n    5.9)].\n  \n   \n                     \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients\n  \n   [see Warnings and Precautions\n   \n    (5.7,\n   \n    5.8)]\n  \n   .\n \n  \n                     In the setting of coronary artery bypass graft (CABG) surgery\n  \n   [see Warnings and Precautions (\n   \n    5.1)]\n  \n   .",
    "drug": [
        {
            "name": "EC-NAPROXEN",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00788"
        }
    ]
}